Sharma, N., Pennell, N., Nickolich, M., Halmos, B., Ma, P., Mekhail, T., Fu, P. and Dowlati, A. (2014) Phase II Trial of Sorafenib in Conjunction with Chemotherapy and as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer. Investigational New Drugs, 32, 362-368.
http://dx.doi.org/10.1007/s10637-013-0061-6

has been cited by the following article:

• TITLE: Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  AUTHORS: Karin R. Purshouse

  KEYWORDS: Oncology, Small Cell Lung Cancer, Targeted Therapy, Drug Development

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.3, August 22, 2014

  ABSTRACT: Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.